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Abstract
Background: A meeting was organized by Drugs for Neglected Diseases initiative (DNDi) and the Institute Pasteur (IP),
Paris, to review the treatment for all forms of cutaneous leishmaniasis (CL) and to propose a strategy for the
development of new efficacious and affordable treatments.
Method: The global burden of CL was discussed with respect to financial impact; relation to poverty; the stigma of CL
lesions and scars (particularly in young women); lack of effective, affordable, easily implemented tools and political will
and resources to implement available control tools; and lack of input from pharmaceutical and biotechnology companies
to develop new drugs and vaccines.
Results: According to the experts from different endemic countries present, the financial and social burdens of CL are
high, but we have limited quantitative data. The analysis of published trials indicates that the quality of most trials is poor
and requires both improvement and standardization. The available drugs are inadequate. Criteria by which different CL
types could be prioritized as target disease were set. These criteria included: severity of the disease; lack of response to
available drugs; overall incidence and prevalence of the disease; sequelae of the disease, (including recidivans and mucosal
leishmaniasis); the impact of treatment of individuals on control of transmission and lack of other major parties involved
in drug development. Based on these, the anthroponotic CL and its sequel "recidivans" caused by L. tropica and CL caused
by L. braziliensis and its sequel, mucosal leishmaniasis were considered to be the target diseases.
The mechanism for controlling Leishmania infection to reach a stable self healing process is a balanced immune response.
Immune stimulation during chemotherapy can enhance cure. There is no adequately effective vaccine, but some
encouraging results have been obtained with whole killed Leishmania parasites or imiquimod (an immuno-modulator) plus
antimonials. Further studies are needed. One safety/immunogenicity clinical trial is currently ongoing with a Second
Generation Vaccine (SGV).
Conclusions and recommendations: There is an urgent need for new treatments for all CL types. CL should be
considered as a neglected disease and organizations, such as DNDi, should include it in their list of target diseases. It was
agreed that immuno-chemotherapy (with "therapeutic" vaccines or immunomodulators) has a strong potential to make
an impact as a new therapy of CL with the view of shortening/reducing duration and dose of drug treatment and
preventing resistance. There is also a need for safe, affordable and efficacious new chemotherapeutics. The quality of
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clinical trials needs to be enhanced and standardized. Short and long-term objectives and activities were defined as a part
of meeting recommendations.
Review
A meeting, organized by the Drugs for Neglected Diseases
initiative (DNDi) and IP, was held to review the present
situation of treatment of all forms of CL, to elaborate on
the socio-economic impact of this disease on individuals
and the financial burden to endemic countries, to identify
gaps in knowledge and tools and to recommend alterna-
tive models for developing new safe, efficacious and
affordable treatments. Invited participants were experts
actively engaged in research and treatment of cutaneous
leishmaniasis, representing experience in over 14 coun-
tries (see Table 1 for list of participants). The meeting fol-
lowed immediately after another organized by IP, Pasteur
Institute Tunis and the Walter Reed Army Institute of
Research (WRAIR) on a new topical treatment in clinical
development for CL caused by L. major so that latest
progress could be shared. All participants submitted a
brief overview of their presentation, distributed to all
prior to the meeting. Short presentations were followed
by sessions allotted to brain-storming and discussions.
Following the first afternoon of presentations, partici-
pants were divided into two groups to discuss short term
(3–5 years) and long term (up to 10 years) objectives and
priorities, and to develop decision matrices for these
objectives (Fig. 1 &2). Participants considered CL and its
sequels that encompass many different disease entities
with different epidemiology, causative Leishmania spp.,
natural history, public health importance, the role of case
treatment in the control of disease, the response to avail-
able treatment, and new and required tools for treatment.
The need to identify the target diseases, to develop a target
product profile (TPP, See Appendix 1 ACL-TPP.xls) and a
set of recommendations by consensus were agreed.
To begin, Ms. M. Boccoz, Director of International Rela-
tions of IP welcomed the guests and as IP is a founding
partner of DNDi, was pleased that the meeting was being
held at the Institute which looked forward to further col-
laboration and participation in the global fight against
"Neglected Diseases" with DNDi. Dr Croft, Director, R&D
DNDi also welcomed the participants on behalf of DNDi,
and outlined the goals and activities to: (a) Develop new
drugs for people suffering from neglected diseases (b)
Ensure equitable access to new and field-relevant health
tools, (c) Raise awareness of the need to develop drugs for
neglected diseases and (d) build public responsibility and
leadership in addressing needs of these patients. DNDi
was established in July 2003 as a virtual model, working
with institutions around the world to meet the specific
needs of most neglected diseases. DNDi has developed
partnerships with institutes in disease-endemic countries
and counts on their involvements. Currently DNDi has
over 20 projects in 2006 portfolio, from discovery to clin-
ical trials on human African trypanosomiasis, visceral
leishmaniasis, cutaneous leishmaniasis, Chagas disease
and malaria. The future focus will be on the trypanosomi-
ases and leishmaniases with projects identified proac-
tively for further exploration. The first success for DNDi
will be the registration of the anti-malarial artesunate/
amodiaquine co-formulation in early 2007 (see [1] for
further information).
Workshop participants were asked to discuss all treatment
modalities available and address the following questions
and make recommendations:
￿ Based on available data, what should be the level of
involvement of DNDi?
￿ Is there one treatment for all? Or do different forms of
CL require different approaches?
￿ Is there a priority to address a particular form of CL?
The participants were urged to review, discuss (and dis-
turb) present dogmas and consider current and long term
opportunities to be captured in the report of the meeting.
The output of the meeting including the recommenda-
tions to DNDi (short term and long term) will be used as
the basis for a Strategy Document on CL to inform deci-
sions for inclusion of projects in the DNDi Portfolio.
Abstracts of presentations
Below are excerpts from the presentations of participants
and the discussions that followed.
Dr J. Alvar (WHO) started the participants' presentations
by reviewing the global public health importance of CL. A
total of 11.8% of total worldwide DALYs by all leishmani-
asis occurs in the Eastern Mediterranean countries, where
CL is concentrated. In most cases, the per capita income in
the leishmaniasis endemic-areas is substantially lower
than the national per capita income.
He reviewed the relationship between poverty and CL in
different countries where an estimated 90% of global
cases occur (Table 2). In Kabul Afghanistan, there were
33,723 cases reported for the population of 6.3 million.
The per capita income of highly affected areas was $160/
year compared to the national per capita GDP of $190 forKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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2002. He stressed that disfigurement caused by CL leads
to stigma, isolation and barrier to marriage, especially for
girls. Patients are reservoir of infection and delay in treat-
ment increases the chance for transmission. Proximity of
cases with uninfected individuals creates a risk of trans-
mission and crowding is one aspect of poverty in many
urban communities. CL has creates a burden on national
economy. Seventy seven % of men in Ecuador believe CL
diminishes their ability to work. The cost of treatment is
high and in most cases beyond the means of affected peo-
ple. Dr Alvar urged DNDi to get involved in this truly
neglected disease and particularly consider ACL in South-
, and South Western countries of Asia.
Discussion: CL is mostly the disease of poor people. It
is a spectral disease and represents many forms. Some
forms are self healing but leave scars with strong social
stigma and marginalization. Other forms are non-heal-
ing or chronic with sequels leading to disfigurement or
mutilation of face with severe social and economic con-
sequences. There is not adequate attempt to develop
new treatments. DNDi is urged to get involved and
develop affordable, efficacious and safe short treat-
ments (preferably topical for uncomplicated CL) that
do not require demanding health system infrastructure.
A. Llanos-Cuentas described the CL situation in Peru,
where disease distribution was compared and contrasted
with certain social indicators in various areas of the coun-
try. He concluded that the primary factors which increase
the risk of transmission and disease are ecology, and
social factors such as the number of physicians/10,000
population, fertility rate, schooling, and poverty
(income), while parasites, vectors and reservoirs are sec-
Table 1: List of Participants
Last Name First Name City Country email
Alvar Jorge Geneve Switzerland alvarj@who.int
Arana Byron Guatemala City Guatemala baaz@cdc.gov
Ben Salah Afif Tunis Tunesia Afif.bensalah@pasteur.rns.tn
Bogdan Christian Freiburg Germany christian.bogdan@uniklinik-freiburg.de
Buffet Pierre Paris France pabuffet@pasteur.fr
Croft Simon L. Geneva Switzerland s.croft@dndi.org
Don Robert Geneva Switzerland rdon@dndi.org
Garnier Tracy Herts UK t.garnier@herts.ac.uk
Ghalib Hashim Geneva 27 Switzerland ghalibh@who.int
Grogl Max Hawaii USA max.grogl@haw.tamc.amedd.army.mil
Hailu Asrat Addis Ethiopia hailu_a2004@yahoo.com
Hommel Marcel Paris France mhommel@pasteur.fr
Khamesipour Ali Tehran Iran Khamesipour_ali@yahoo.com
Lang Thierry Paris Cedex France tlang@pasteur.fr
Lecoeur Hervé Paris France helecoe@pasteur.fr
Llanos-Cuentas Alejandro SMP Lima Peru allanos@upch.edu.pe
Magill Alan Washington DC USA alan.magill@na.amedd.army.mill
Matlashewski Greg Montreal, Quebec Canada greg.matlashewski@mcgill.ca
Meaume Sylvie Ivry sur Seine France Sylvie.meaume@cfx.aphp.fr
Meheus Filip Antwerp Belgium filip.meheus@ua.ac.be
Milon Geneviève Paris Cedex 15 France gmilon@pasteur.fr
Modabber Farrokh Ferney-Voltaire France modabberf@yahoo.com
Morizot Gloria Paris France gmorizot@pasteur.fr
Pecoul Bernard Geneva Switzerland bpecoul@dndi.org
Rabello Ana Belo Horizonte Brazil ana@cpqrr.fiocruz.br
Rizzo Nidia Guatemala City Guatemala nrrz@cdc.gov
Royce Catherine Geneva Switzerland croyce@dndi.org
Sacks David Bethesda USA dsacks@nih.gov
Stahl Kurt-Wilhelm Freiburg Germany kwstahl@web.de
Torreele Els Geneva Switzerland etorreele@dndi.org
Unable to attend
Boelaert Marleen Antwerpen Belgium mboelaert@itg.be
Brewer Thomas Seattle, WA USA Thomas.brewer@gatesfoundation.org
Davis Heather Ottawa, Ontario Canada hdavis@coleypharma.com
Khalil Eltahir A.G. Khartoum Sudan eltahirk@iend.org
Olliaro Piero Geneva Switzerland oliarop@who.int
Reed Steven G. Seattle, WA USA sreed@idri.orgKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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ondary factors. He indicated that the distribution of CL in
Peru can almost be superimposed by areas of low social
factors. Loss of income due to CL is an important factor in
poverty.
Dr A. Rabello presented the situation in Brazil. CL is con-
sidered to be an important public health problem in some
states as the number of cases has increased many folds in
recent years. An interesting observation is that the inci-
dence of disease is inversely related to GDP per capita for
different states (Fig. 3). The cost of treatment with antimo-
nial in Brazil is about US$ 150. However, Ambisome is
used at extremely high cost. It was estimated that US$
500,000 was spent to treat 95 patients; the cost to treat
with antimonials for 35,000 patients was US$ 2.5 M. This
is a considerable burden on health system in Brazil.
Dr N. Rizzo described the situation in Guatemala, where
CL is rated fourth as the most frequent condition and sixth
as most serious disease in the area. There is no official sup-
port for diagnosis, treatment or follow up. The cost of
treatment by antimonial is about $252.00/patient which
is the equivalent income of 2.4 months on average. CL is
a rural disease and only 35% of rural population has a for-
mal job with minimal salary of US $5.15 per day. Even
when treatment is offered free of charge, the cost to
patients is about US $82 or equivalent to 73% of an aver-
age monthly salary.
Schematic representation of decision matrix for short-term objectives (3 years) Figure 1
Schematic representation of decision matrix for short-term objectives (3 years). ctivities related to trials of 
selected combination of anti-parasitic drugs will proceed in parallel with development of immuno-chemotherapy approach 
using available drugs, immun-modulators, with or without leishmanial antigens. Efforts will be focused on enhancing the quality 
of clinical trials through development of standard protocols and ICH-GCP training.
Efforts Toward Short Term Objectives (up to 3 Years 
Year-1
Year-2
Set up a Clinical Trial Platform for CL
•Develop Standard Protocol
￿Set up communication with all sites
Select trial sites and prepare for trials
￿Adapt the standard protocol
￿Enhance c-GCP through preparation for a specific trial 
(i.e. establish ERB, DSMB,…
￿Set up GCP Training Workshops
￿Set up infrastructure for the trial … 
Tox studies of selected combinations (if necessary)
Standardize killed parasite vaccine:
￿Grow in defined medium
￿Establish potency assay
￿Develop lot release test
Follow Second Generation Vaccine
￿Develop in collaboration 
Conduct Phase 1-2 trials of combined drugs
￿Short term + topical
￿Short term other combination to 
selected
Conduct Phase 1-2 trials
￿Short term drug + Immuno-modulator
(Imiquimod, CpG)
￿Short term drug + therapeutic vaccines
Antiparasitic
Immunomodulator
Year-3
Decision Matrix for Short Term ObjectivesKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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Dr F. Meheus had worked on VL in the Indian subconti-
nent and reported that the cost before starting treatment
could be substantial. In India there is an average of 7 visits
before starting treatment. In addition, the cost of treat-
ment with antimonial is a great burden and beyond the
means of most patients. For CL the cost of treatment is
lower as there is no hospitalization, nevertheless it is not
affordable for most patients.
Discussion. The presentations on socio-economic stud-
ies were discussed together. There is a paucity of socio-
economic studies, the available indicators used (DALY's
and mortality) are not exactly applicable and do not
reflect morbidity caused by CL. Well designed studies
and relevant indicators are need.
Dr A. Magill discussed the adverse events associated with
current chemotherapy and stressed that safer and more
efficacious drugs are urgently needed. Globally, the first
line drug against CL and its various sequels is penta-valent
antimonials (Sb+5). A full course of Sb+5 is poorly toler-
ated, requires careful monitoring to prevent severe and
serious adverse events (SAE), is given parenterally which
is inappropriate for uncomplicated CL. In the worst sce-
nario, it can cause death if not carefully monitored, trans-
mit blood born infection. Antimonials are
contraindicated in pregnancy, patients with significant
renal and hepatic disease and diabetes. Common adverse
events are myalgia, joint stiffness, malaise, anorexia,
transaminitis, increased amylase/lipase, and bradycardia
with ECG changes of prolongation of QT interval and T-
Schematic representation of decision matrix for long-term objectives (7–10 years) Figure 2
Schematic representation of decision matrix for long-term objectives (7–10 years). Two parallel activities similar 
to those in short-term objectives is envisaged. New potential drug identified through synthesis/screening against L. donovani will 
be tested against isolates of Leishmania causing CL in a mouse model. Active compounds will be identified for further develop-
ment and eventually tested in combined immuno-chemotherapy trials. New immuno-modulators will be tested in the B6 
mouse model; however, the CpG's with human-specific motifs being developed for cancer therapy will be adopted for CL 
treatment.
antiparasitic immunomodulator
Actives: test on panel of >5 CL 
isolates (L.tropica, L.braziliensis)
In vitro activity IC50: 
L.donovani amastigotes (in HMPC)
In vivo efficacy: L.major
infection in C57Bl/6 mice
In vivo efficacy: L.major or 
L.Mexicana in C57Bl/6 mice
CpG, others from literature, in 
clinical development, on market
In vivo efficacy: L.major
infection in C57Bl/6 mice
Th1-type
i.m./i.d./s.c. or topical
Available for CL
+ adjuvant?
Combination therapy
+ adjuvant?
Parameters:
- Parasite load
- Pathology
- Type of T-cell response
In vivo efficacy: L.braziliensis
in hamster model
Added value of monkey model??
Choice based on:
-E f f i c a c y
- Mode of action
- Delivery
-c o s tKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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wave inversion. Less common AEs include hepatotoxicity,
hemolytic anemia, nephrotoxicity, pancreatitis.
Angioedema, anaphylaxis, post-Rx zoster have also been
seen but only rarely.
Other medications that have been used as second line
treatments or are in use without adequate assessment of
their usefulness have not been superior to replace Sb+5.
These include topical application of thermotherapy, cryo-
therapy, intralesional Sb+5, topical paromomycin oint-
ments/gels and topical imiquimod together with other
treatments. The systemic treatments include amphotericin
B, pentamidine, oral azoles, oral topical miltefosine, dap-
sone, allopurinol, and many others. These are either not
fully effective or affordable and are too toxic or require
long-term administration. There have been numerous tri-
als published however a new, non-invasive, efficacious
and affordable treatment is urgently needed.
Discussion: Clearly the present available medications
are toxic and side effects are accepted because there are
not many choices. There is a need to develop safe, effi-
cacious non-invasive and affordable new treatments for
different forms of leishmaniasis.
Dr P. Olliaro's critical review of published studies from
1994–2005 on clinical trials of CL was presented by F.
Modabber (he was unable to attend). A total of 75 articles
were reviewed of which 42 trials were controlled. Twenty
seven trials without control (C) were published, which for
a generally self-healing disease for many CL's provide very
limited information.
Of the 42 controlled, 20 were randomised, double-blind
with placebo control, 18 were either not randomised, else
were not double-blind. These are also subject to bias out-
comes. A total of 4650 subjects (mean 111/study, ranging
from 20 – 400) were enrolled of whom 90% (4207) were
evaluable in per-protocol analyses (Fig 4).
In conclusion, the paucity of well designed trials is appar-
ent. This has lead to our inability to judge the true efficacy
of many agents and their comparable value. DNDi is
urged to create a platform for establishing standard trial
designs and enhancing capacity for trials with highest cur-
rent Good Clinical Practices guidelines. In particular, Dr
Olliaro's report emphasises that studies for CL should be
comparative (or placebo controlled whenever possible),
randomised and double-blind. As topical placebo may
have an effect on the healing process, the natural history
of the disease in the trial area must be established, else, if
considered ethical, delayed rescue design should be con-
sidered, with CL forms that do not evolve rapidly or have
severe sequels. The design should be amenable to individ-
ual patient data (IPD) for meta analyses. As a certain % of
CL lesions heal spontaneously (even after years), the dura-
tion of the disease as an inclusion criterion is essential.
Standardised definition of case and outcomes are very
important if studies are to be compared. As well, reporting
should be uniformed as per CONSORT statement (see
http://www.consort-statement.org). It is suggested to use
survival analysis (Kaplan-Meier) plots for rate of healing,
use hazard rates, compare with a logrank test or the Man-
tel-Haenszel chi-square. Sample size should be adequate
to provide sufficient power for multivariate analyses
Table 2: Relationship between poverty and CL incidence
Poverty and other indicators for 90% of global CL cases
% Population earning < 1$/day Years of Life Expectency % With access to improved water sources Literacy rate (for >15 yrs old)
Afghanistan* ? 46 13 36
Algeria <2 69.2 89 67.8
Bolivia** 14.4 63.2 83 86
Brazil 9.9 67.8 87 87.3
Colombia** 14.4 71.8 91 91.9
Iran <2 69.8 92 71.1
Peru 15.5 69.4 80 90.2
Pakistan 13.4 60.4 90 44
Saudi Arabia ? 71.9 95 77.1
Sudan* ? 55.4 75 58.8
* = Categorized as Least Developed Country (LDC)
** = Not included in earlier lists of countries with highest
leishmaniasis burden, incidence has increased substantially
Only two countries are listed as LDC, however other countries have pockets of poverty ranging from <2% to 35% of the population. Inclusion of 
non-economic indicators provides a more comprehensive picture of poverty. (adopted from L. Alvar, WHO).Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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allowing influence of age, sex, type and number of lesions,
previous duration of illness, etc. DNDi could prove a great
impetus by developing a platform for CL clinical trial to
increase the standard of evaluation of new treatments
Discussion: Lack of adequate drive to develop new
treatment for CL is apparent from the published data.
Designs of studies are highly inadequate, variations in
case definitions and end points make comparison of
trials impossible. Contradictory results may well be due
to these inadequacies. DNDi is urged to develop a plat-
form for communication on clinical trials of CL glo-
bally and to develop standardized model protocol and
increase capabilities for performing GCP-ICH level clin-
ical trials.
Dr S. Meaume described several approaches for promot-
ing healing of cutaneous lesions, based on her knowledge
of the process of wound healing. Initially, a blood cloth is
formed, polymorphs migrate to wound margin, epithelial
cells migrate over the wound surface and stimulated by
macrophages lay collagen fibres and, when re-epitheliali-
zation is complete, the blood cloth is discharged. The first
objective of therapeutic approach of wounds is to pro-
mote these processes. The classical paper of Winter GD [2]
showed that a moist environment accelerates wound heal-
ing. The second objective is the closure of the wound and
filling of the depression created in order to minimize scar-
ring. Hydrocolloids with an internal layer of carboxyme-
thyl cellulose and an external layer of polyurethane foam
are used in all the stages of healing. When wound exudate
is moderate, polyurethane films are adequate. Profuse
exudation requires alginates, because of their very high
absorbency. Hydrocellular dressings and foam have about
the same use as alginates. Hydrogels contains more than
80% of water that can be liberated in the wound. Charcoal
dressings reduce exsudates and bad smells. Dr Meaume
considered that a polyurethane films widely available and
affordable would be best for use on lesions of CL. Poten-
tial skin irritation induced by repeated application of
adhesive dressings would be easily controlled by applica-
tion of widely available affordable ointments (Mitosil)
and/or local cortisone on the skin surrounding the CL
lesion, when indicated.
Discussion: To promote healing of CL lesions, methods
used in wound healing should be employed. Affordable
occlusions are available that can safeguard against
super infection and create a moist environment for
accelerating healing process and reducing scars.
Dr G. Milon attracted the attention to the persistence of
parasites in developmental stage following the control of
cell-cycling Leishmania amastigotes in C56Bl/6 mice. Are
these amastigotes non-cell-cycling Leishmania that persist
in the upper dermis and are those the only ones that are
transmissible to the sandfly vector? These parasites are not
readily quantified by classical techniques, or their quanti-
fication is still expensive (quantitative Real Time PCR). Dr
Milon warned that – as in this mouse model-, humans
may harbour Leishmania that were reaching this develop-
mental stage after patients were treated. If so, then it could
be explain why long after recovery from the primary
lesion some could enter the cell-cycle phase and create
secondary lesions. In addition, these quiescent parasites
could be transmissible to the sandflies. A treatment
modality that could eliminate these "dormant/quiescent
non cycling parasite population" might be needed for
long term control of anthroponotic (or canine) leishma-
niasis in endemic areas.
Dr T. Lang described a system (and later demonstrated it
to some participants) by which the course of Leishmania
infection can be monitored in the ear lobe of C56Bl/6
mice that received 104 luciferase – expressing L. major met-
acyclic promastigotes intradermally. The bio-reagent can
then be measured quantitatively during the rise and fall of
the parasite population (Fig 5). Ongoing explorations for
detecting very low number of parasites are expected to
allow the detection/quantification of the dormant popu-
lation in the healed ear and in distant cutaneous sites. Dr
Lang indicated that this system would be adaptable to
screen treatment modalities, new compound, and drug
combinations and drug+ immuno-modulator. The system
would be able to monitor the initial fall of parasite burden
but also very soon persistent organisms over a long
period. He also noted that a quantitative real time PCR is
now also available for addressing this latter issue.
Poverty and CL Figure 3
Poverty and CL. Inverse relationship of incidence of CL 
(green diamond) to GDP/capita (black diamonds) in various 
states of Brazil. AC = Acre, AM = Amazonas, PA = Para, RO 
= Rondonia, RS = Rio Grande do Sul, SC = Santa Catarina, SP 
= Sao Paulo. (Adopted from A. Rabello).
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Discussion: Measurement of parasite loads in experi-
mental animals used for treatment evaluation has been
labor-intensive. The new technology of using luciferase
expressing Leishmania and bio-photonic imaging sys-
tem provides a strong tool to study the efficacy of vari-
ous treatments in the L. major/C57Bl/6 mice. There is a
need to develop other animal models for different
Leishmania  species using this technology. Some
immuno-modulators (cytosine-phosphate-guanosine
oligodeoxynucleotides, CpG's) are species-specific
hence it should be noted that although the general
approach can be evaluated, the individual compounds
would need to be identified for human use.
Dr S. Croft reviewed compounds and drugs with some
potential for treatment of CL. Based on experimental in
vivo data there are disappointingly few candidates. These
are inhibitors of sterol biosynthesis (anti fungal drugs),
propyl-quinolines, Chalcones (licochalcones), naphto-
quinines (buparvaquone, see Dr Garnier, below), diami-
dines, bisphosphonates, azithromycin, and saponisides.
DNDi's VL strategy which includes synthesis and screen-
ing will generate new chemical entities. Those with activ-
ity against L. donovani, should be tested against CL causing
organisms.
Discussion: With limited resources available, a specific
discovery program for CL producing Leishmania species
does not seem justified at this time. However, lead com-
pounds and drugs identified through the discovery
strategy of DNDi for VL should be tested against CL-
producing species.
Analyses of published clinical trials involving CL Figure 4
Analyses of published clinical trials involving CL. Of 75 studies only 20 were randomized, control trial (RCT), double 
blind (DB) with placebo control (PC). There were 27 trials that had no control arm. For a self healing disease, a control arm is 
necessary if it is ethically correct. There is a need to improve the quality of clinical trials.
design n
non-controlled 27
controlled 42
RCT 18
RCT-DB 4
RCT-DB-PC 20
others 3
unknown 3
total 75
಴ 4650 patients (mean 111/study,
range 20-400)
಴4207 patients (90%) evaluable in
the per-protocol analyses.
arm           n
Intralesional 12
Parenteral 30
Topical 13
Oral 18
Total Treatment arms 73
Placebo arms 16
Grand total 89
DATABASE
Iran 26%, Colombia 17%,  Brazil 13%
Disease in 75 papers (77 study countries)
53% 43%
1%3%
Old World
New World
Old+New
NA
TREATMENT (all studies)
Antimony (Injection + intrales) = 27
Other injections = 4
Topical : Paromomycin = 12; others = 9
Oral: Azoles = 8; others = 7Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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Dr B. Arana reviewed the clinical trials with oral drugs
against CL caused by different Leishmania species. These
included miltefosine, ketoconazole, itraconazole, fluco-
nazole, allopurinol, dapson and oral zinc sulphate. Most
trials were open, non-controlled, inadequately explained
or reported with small sample size. As these were done in
different clinical scenarios, comparison of results were not
possible. Generally the duration of treatment is long (6–9
weeks) with oral drugs i.e, 6–9 weeks for ketoconazole, 4–
9 weeks for miltefosine. The cost of azoles and miltefosine
are prohibitory, allopurinol is not effective alone and was
shown to be beneficial only in combination with Sb+5.
Discussion: Azoles are still expensive and will probably
remain so after their patent protection is over. The long
duration of treatment required make their use less
desirable. Alternative drugs should be sought. The
development of miltefosine for different indications,
including CL in different foci is ongoing outside DNDi.
DNDi should only monitor these developments.
Dr Afif Ben Salah presented the outline of a Phase 2 dou-
ble-blind randomized, placebo-controlled (DBRPC) clin-
ical trial of WR279396 (a new formulation of
paromomycin) recently being conducted in Tunisia and
France on 92 patients with CL caused by L. major (ZCL).
He emphasized the problem of cost, lack of efficacy and
poor availability of Sb+5 in the region, Maghreb (Tunisia,
Algeria, Morocco), with an estimated 300000 CL cases
caused by L. major each year. Patients were treated for 3
weeks with the ointment (or placebo) and covered by an
adhesive polyurethane dressing. Results are expected in
early 2007. A second Phase 2 study is ongoing to evaluate
the influence of occlusion and a Phase 3 pivotal trial is
being planned. This new paromomycin formulation (i) is
manufactured with active compounds that have been in
human use for decades, (ii) has been developed according
to industry/FDA standards, (iii) should be affordable, (iv)
should be tested for efficacy against other CL clinical
forms/infecting species, particularly L. tropica, should the
ointment prove to be efficacious.
Dr. Max Grögl summarized the results of a 2-day meeting
(15th–16th of June) in Paris that brought together repre-
sentatives from key organizations interested in the new
product of Walter Reed Army Institute Of Research
(WRAIR), the new ointment, WR279396. The meeting
was organized by IP Paris, IP Tunis, and WRAIR and
focused on a second generation topical treatment for CL.
The format of the meeting was a combination of summary
presentations of the development phases of WR279396
followed by an open dialogue among the meeting partic-
ipants (DNDi, TEVA Pharmaceuticals-USA, Pasteur Insti-
tute, Tunis, MOH Tunis, Institut Pasteur Paris, US Army
Medical Research and Materiel Command-USAMRMC) to
arrive at goals and objectives for the product and the
requires action plans necessary to achieve these goals.
DNDi representatives (Drs Croft and Don) were invited
and participated. Dr. Grogl indicated that for more than a
decade, the USAMRMC has been actively engaged in the
development of WR279396, a new topical therapeutic for
the treatment of cutaneous leishmaniasis. That the stead-
fast support and combined work from the triad of organ-
izations comprised of the Institut Pasteur Tunis, Institut
Pasteur Paris, and US AMRMC, has offered them with
clinical capabilityies that they hope will culminate in
WR279396 becoming the next new approved drug to treat
CL. Dr Grögl indicated that DNDi will be kept abreast of
all developments, and that should the results of the Phase
3 trial mentioned by Dr Ben Salah, above, indicate suffi-
cient efficacy, the ointment would be widely available for
treatment of CL caused by L. major to all those who need
them. The ointment would be initially registered in the
U.S., however after registration it is planned to transfer the
technology for production of the ointment to Tunisia.
Discussion on the new WRAIR ointment: The results of
phase 2 and the pivotal phase 3 trials are crucial and
anxiously awaited. The close contact between WRAIR
and DNDi on development of this ointment is highly
encouraged and the offer of availability of the ointment
at low cost following its registration as well as transfer
of technology is much appreciated.
Dr A. Rabello presented laboratory and some preliminary
clinical results of a new gel formulation of paromomycin.
The gel consists of 10% paromomycin in 1.5% hydroxi-
ethylcellulose in water. Absorption of paromomycin in
this gel to skin was 205X increased as compared to that of
a paromomycin ointment in a modified Franz diffusion
chamber, using mouse skin. Application of this gel along
with systemic antimony 5 mg SbV/kg was as efficient as 20
mg Sb+5/kg in L. amazonensis-infected mice. The adminis-
tration of the gel alone was as efficient as 20 mg Sb+5/kg
in  L. braziliensis-infected hamsters. The technology of
preparation of this gel has been transferred to a pharma-
ceutical company in Brazil and pre-clinical development
has been initiated and a clinical trial is being set-up
(pending ANVISA, the Brazilian Regulatory Agency,
approval) with the support of Fundação Oswaldo Cruz in
Belo Horizonte and Três Braços – Bahia, to test this gel in
humans.
Dr Rabello also reported that the results of a preliminary
trial of oral azithromycin in patients with CL caused by L.
braziliensis  in an open cohort of 16 patients are very
encouraging, confirming previous in vitro data.
Discussion: The experimental results are very encourag-
ing. Much discussion was focused on the ethical consid-Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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eration of topical treatment of CL caused by L.
braziliensis. The dogma that systemic treatment is
required to prevent development of mucosal lesions
was questioned. Dr P. Buffet presented analyses that
indicated that first line topical treatment of these CL
cases might be both ethical with respect to risk/benefit
and cost/benefit consideration. In addition, it has been
shown that topical heat treatment of lesions in Brazil,
induces a systemic immune response and should not be
considered as only a local reaction.
Topical treatment of lesions caused by L. braziliensis is
probably both ethical and desirable. An expert review
and analysis of peer reviewed literature would be help-
ful.
Dr A. Khamesipour presented the results of 2 published
trials conducted in Iran with the ointment containing
15% paromomycin, 10% urea in white paraffin, originally
developed by Neal and colleagues. The first was a two
arm, DBRPC trial of 2-week treatment (2 WK) on a total
of 251 patients with lesions < 3 months of duration. It
showed a transient but significant reduction in parasito-
logical cure at the end of treatment, but no advantage in
cure rate (complete re-epithelialization). The Second was
a DBRPC trial of 4-week treatment (4-WK) vs. 2-WK active
treatment plus two weeks placebo on 216 evaluable
patients from a focus of ZCL, the same as the first trial.
There was a significantly (p = 0.05) higher clinical cure
rates for 4-WK group (80/108, 74%) on day 29, vs. 64/108
(59%) for 2 WK group. On day 45, there was a significant
(p = 0.005) difference between the two groups with
respect to parasitological and clinical cure (44%vs.24%)
in favor of 4-WK. On day 105, the results favored those
with 4-week treatment but the difference was no longer as
clearly significant (p = 0.06). It was stressed that the dura-
tion of the disease prior to initiation of CL trials is crucial,
as ZCL is by and large a self healing disease within 4–9
months. From this trial, the true efficacy of the ointment
should be considered to be only about 35–40% (the dif-
Real time quantitative measurement of L. major infection in C57/Bl mice Figure 5
Real time quantitative measurement of L. major infection in C57/Bl mice. Mice were infected with 104 luciferase – 
expressing L. major metacyclic promastigotes intradermally. The bio-reagent can then be measured quantitatively during the 
rise and fall of the parasite population at various times. (adopted from T. Lang's presentation)
Day 18 Day 32 Day 4
Fig. 5
Real time quantitative measurement of L. major infection in C57/Bl mice  (adopted from T. Lang)Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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ference between active treatment and placebo), as 30–
40% would have self healed giving an efficacy of 75–80%
total (Fig 6). This ointment may be considered as first line
treatment for uncomplicated ZCL[4], which according to
WHO should not be treated with Sb+5, a recommendation
that is seldom applied as patients demand treatment. Pre-
liminary trials of this ointment on ACL have shown no
advantage in cure of lesions.
Discussion: There are indications that this ointment is
not efficacious against ACL. However, one published
trial [3]showed that topical paromomycin (P-ointment)
twice daily for 15 days was significantly more efficient
than oral ketoconazole in the L. tropica focus of Urfa,
Turkey. At 4 weeks of treatment, 37.5% of patients were
cured and 20% improved. No further follow-up data
were provided. There are conflicting reports of efficacy
of this ointment within Iran. Most trials suffer from
inadequacies related to design, sample size and stand-
ardized definitions of case and endpoints. Only com-
parative parallel studies of different ointments can be
used to evaluate different ointments. GMP preparation
of all material used in phase 3 studies can not be over
emphasized and results with home-made material
should be disregarded.
Dr KW Stahl presented the results of two approaches
recently used in Afghanistan (i) Coagulation and evapora-
tion of Leishmania infested tissue by electro-thermo-cau-
terisation, (ii) Moist wound treatment with and without
pharmaceutical chlorite DAC N-055. The efficacy of both
approaches is being assessed with the view of developing
an affordable, efficacious, safe and doable treatment for
the most unprivileged population of Afghanistan, living
under very difficult conditions. In Afghanistan, there is at
present no infrastructure to guarantee the quality control
of drugs, their proper handling and use and the problem
of ACL continues to impose heavy morbidity (see Alvar,
above). Dr Stahl's group at the German Medical Centre,
Kabul, have chosen a topical physico-biochemical
approach to CL treatment rather than Sb+5, which would
not require blood tests for monitoring side effects, or
increase the chance of selecting resistant organisms
already seen in the region. Local anaesthetics were used
while applying electro-thermo-cauterisation as it can be
painful. Occlusion with a polyurethane dressing with/
without a gel was efficient in most patients. Parallel study
of parasite loads using the limiting dilution technique
showed that parasite loads at the beginning of treatment
was sometimes very high (up to almost 109 parasites per
gram). Most patients healed before D45 after a single
application (Fig 7). As the study is still ongoing, the exact
efficacy of this approach can not be given at this time, but
the results are very encouraging. Over all, satisfactory
results have been obtained under the difficult conditions
with very limited resources. Should the results indicate,
efforts should be made to bring pharmaceutical chlorite
DAC N-055, a very inexpensive drug in Germany, to the
international pharmacopoeia.
Discussion: The efficacy of treatment with electro-
thermo-cauterisation is not known yet, but will be
known when the studies are complete within the next
year. At this time the group did not seem to recommend
use of equipment and repeated contact with a health
worker. It is hoped that new innovative strategies can
be developed for CL in remote areas as well which
would make the use of electric equipment difficult if
not impossible. However the use of DAC N-055 and
moist occlusion was interesting. The work of German
Group in Afghanistan is commendable. Afghanistan is
the focus of one the worst ACL epidemics in history.
Collaboration and communication of the Group with
the proposed DNDi clinical trial standardization plat-
form is highly recommended.
Dr T. Garnier presented data on Buparvaquone (BPQ)
topical treatment of L. major infection in Balb/c mice. BPQ
was selected because of its in vitro and in vivo activities
against several Leishmania species and its physical-chemi-
cal properties. Ideally, a topical drug candidate should
have a small molecular weight (<500 Daltons), low melt-
ing point (m.p.), low hydrophilicity and have few func-
tional groups capable of hydrogen bonding. BPQ has
several physicochemical properties suitable for topical
delivery. It has a MWT of 326.43, m.p. 182.2 – 183°C, 2
hydrogen bond accepting and 1 hydrogen bond donating
groups, poor aqueous solubility and therefore suitable for
topical formulation. Less lipophilic phosphate prodrugs
were designed with the aim of altering physicochemical
properties and improving BPQ skin permeation. Two
BPQ prodrugs have been synthesized, namely
buparvaquone-3-phosphate (BPQ-3-phosphate) and 3-
phosphono-oxymethyl-buparvaquone (3-POM-BPQ),
both of which exhibit a significantly increased aqueous
solubility compared to BPQ, while not greatly increasing
molecular weight. Various carriers ready for human use or
in development were used for delivery of these com-
pounds and tested in the L. major/Balb/c model. Both a
BPQ hydrous gel and a BPQ water-in-oil emulsion signif-
icantly reduced both parasite burden (P < 0.05, 22 days
post infection; as determined by real time PCR) and lesion
size compared to the untreated control (P < 0.0001, 13
days post start of treatment) see Fig 8.
Discussion: BPQ is a registered drug in veterinary use
for treatment of Theileria infection. Hence much infor-
mation of its safety profile exists. It would be useful to
follow development of a topical preparation of this
drug for CL as it is active against many CL producingKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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species. It has not been tested against L. tropica and it
would be of interest to see if it is active against this spe-
cies.
Dr Matlashewski introduced Imiquimod, (1-[2-methyl-
prophyl]-1H-imadazo [4,5c] quinoline-4-amine), which
was developed by 3 M company for the treatment of cer-
vical warts due to human papilloma virus. It is marketed
as Aldara (5% imiquimod cream). Imiquimod and its
more active analog, R848, are synthetic low molecular
imidazoquinoline compounds which are potent
immuno-modulators through activating Toll-Like
Receptor7 (TLR) and TLR8 on human antigen presenting
cells including macrophages and dendritic cells (Fig 9).
Activation of TLR 7/8 with R848 results in secretion of
pro-inflammatory cytokines including IL-12 which leads
to the polarization of naïve T cells into a Th1-type cell.
This leads to polarization of the response toward Th1
response, needed to kill intracellular Leishmania. Imiqui-
mod can activate macrophages to kill intra cellular Leish-
mania. Following the initial successful results against
Leishmania in laboratory, it was quickly possible to pro-
ceed to clinical trials since imiquimod was already used in
humans.
Two clinical trials have been concluded in Peru involving
the treatment of cutaneous leishmaniasis with topical
Aldara (5% imiquimod, donated by 3 M pharmaceuti-
cals) [5,6]. These studies demonstrated that combining
imiquimod treatment with the standard pentavalent anti-
mony treatment is safe and significantly increased the cure
rate compared to treatment with antimony alone in
patients which have failed a previous treatment with anti-
mony (non-healing patients). – see Llanos-Cuentas,
The public health aspect of paromomycin-urea ointment Figure 6
The public health aspect of paromomycin-urea ointment. The true benefit of the paromomycin (aminocidine) oint-
ment in ZCL patients (caused by L. major) in Isfahan, Iran. About 30–40% self heal within 5–6 months from onset of disease, 
With an efficacy of the ointment about 35–40%, 75–80 would cure within this period leaving 20–25% of refractory patients 
who would need other treatment. This figure indicates the importance of a placebo (control) arm in all CL studies. In addition, 
the duration of lesion prior to enrolment into any trial is critical, since with time, more and more cases self heal.
The Public Health Benefit of Aminosidine ointment
Practice:
Rx with antimonials, cryotherapy,
home made medicines, etc
Current WHO recommendation:
*Do NOT treat patients with <3
lesions, uncomplicated and away from
vital organs
*NOT POSSIBLE
PATIENTS DEMAND TREATMENT
From Asilian A. et al. Bull World Health Organ. 81: 353-9, 2003 
Antimonials are becoming ineffective
for this group of patients
Need new drugs or treatment modalityKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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below. Additional clinical trials in cutaneous leishmania-
sis patients which have never before been treated is now
ongoing with DNDi support. This involves (i) combining
topical imiquimod (Aldara) and iv injections of Sb+5; and
(ii) combining topical imiquimod (Aldara) with topical
paromomycin. The second trial involving paromomycin
is potentially important because it is designed to develop
a combination topical therapy which would replace the
need for iv injection of antimonials. Considering imiqui-
mod mode of action, it seems that it can act as an adjuvant
for therapeutic as well as prophylactic vaccination. Further
studies are planned to test this possibilities.
Discussion: Killing of the bulk of parasite by chemo-
therapy followed by stimulating the immune response
in the right direction is the novel approach that DNDi
should consider seriously. Imiquimod, having gone
through safety and initial efficacy trials, is an obvious
choice to be fully studies for maximum effectiveness.
The patent protection of imiquimod will end soon and
hopefully it will be produced as generic and become
affordable. It also be of interest to test the adjuvant
potential of imiquimod should it be necessary to use
leishmanial antigens for immuno-chemotherapy or
immunotherapy.
Dr A. Llanos-Cuentas described the trials of meglumine
antimoniate ± topical imiquimod for cutaneous leishma-
niasis in Peru. [5,6] In a randomized double blind clinical
trial 40 subjects with clinical resistance to antimony were
recruited. All subjects received meglumine antimoniate
(20 mg/kg/day im or iv) and were randomized to receive
either topical imiquimod 5% cream (Aldara; 3 M Pharma-
ceuticals) or vehicle control every other day for 20 days.
Lesions and adverse events were evaluated during treat-
ment and at 1, 2, 3, 6, and 12 months after the treatment
period. All but 2 subjects completed therapy. Mild adverse
events were reported by 73% of the subjects, but only ery-
thema occurred more commonly in the imiquimod group
(P < 0.02). Lesions resolved more rapidly in the imiqui-
mod group: 50% of the imiquimod group achieved cure
at 1 month after the treatment period versus 15% of the
vehicle cream group (P < 0.02); 61% of the imiquimod
group at 2 months versus 25% of the vehicle cream group
(P < 0.03); and 72% of the imiquimod group at 3 months
versus 35% of the vehicle cream group (P < 0.02). Resid-
A patient (Afghanistan) with lupoid CL before and after DAC N-055 therapy Figure 7
A patient (Afghanistan) with lupoid CL before and after DAC N-055 therapy. (Adopted from K-W Stahl, A F Jebran, 
F M Amin, R Steiner, A G Faramol, F Mahfuz, C Kurzmann, U Schleicher, C Bogdan – unpublished. Presented by K-W Stahl).Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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ual scarring in the imiquimod group was less prominent
than in the vehicle cream group (Fig 10). In conclusions,
combined antimony plus imiquimod treatment was well
tolerated, accelerated healing of lesions and and
improved scar quality. This therapy may have particular
advantages for subjects with facial lesions.
In addition to the original open study on 12 patients in
Peru which produced very encouraging results, another
study conducted in Iran was also mentioned which
showed some beneficial effect (Meymandi, personal com-
munication). However there is one report from Iran on CL
caused by L. tropica which showed no added effect by imi-
quimod to antimonial therapy (see Khamesipour, below).
Discussion: Based on previous positive responses, addi-
tional studies with different doses would be of interest.
In addition if imiquimod is active as an adjuvant, its use
in therapeutic vaccines should be considered.
Dr A. Khamesipour reported on the results of two trials in
Iran. First was a three arm trial involving imiquimod
alone (27 patients), imiquimod plus intra-lesional anti-
monial (35 paitents) and intra-lesional antimonial alone
(35 patients) for a period of 6 weeks. The previous history
of treatment in the patients was not known and the study
was not according to a clinical trial protocol, but collec-
tion of records of treatment history. The results indicated
a decrease in size of erythema, induration and ulcer (end
point). There was a slight but definite beneficial effect by
adding imiquimod to antimonial (37% Imiquimod + Sb
"responders" vs. 23% antimonial alone). The second trial
was a randomised, double blind, two arms controlled trial
of 4 week treatment of imiquimod + 2 week antimonial
vs. 4 week placebo + 2 week antimonial in 119 patients
with CL. The results were compared 4, 8 and 20 weeks
after the initiation of treatment. There was no detectable
difference between the two groups at any time point. It
was concluded that with the regimen used, 4 weeks of
treatment with topical imiquimod does not enhance the
response to antimonials.
Discussion: The outcomes of the two Iranian trials were
different. This may be due to differences in the design,
Response to topical treatment with different buparvaquones (BPQ) Figure 8
Response to topical treatment with different buparvaquones (BPQ). BALB/c mice were infected with 2 × 106 L. major 
J118 promastigotes and 20 daily topical application began 3 days post-infection. Both a BPQ hydrous gel and a BPQ water-in-oil 
(w/o) emulsion significantly reduced both parasite burden (P < 0.05, 22 days post infection; as determined by real time PCR) 
and lesion size compared to the untreated control; P < 0.0001, 13 days post start of treatment, (adopted from T. Garnier).
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duration of treatment, history of patients, sample size,
endpoint definition, causative organisms, etc. The
diversity of responses seen here and is observed
throughout CL trials around the world, further indi-
cates the urgent need for standardizing clinical trials of
CL.
Dr F. Modabber reviewed clinical studies on therapeutic
vaccines in cutaneous leishmaniasis. Convit and col-
leagues in Venezuela initiated immunotherapy of CL with
killed Leishmania mixed with BCG. In his review of 11532
cases treated, Convit reported that cure rates varied
between 91.2% – 98.7%; time to cure was similar or only
slightly longer than chemotherapy with 3–4 injections
but the cost and side effects were considerably reduced as
compared to Sb+5 [7]. Side effects of the therapeutic vac-
cine were confined to the site of reaction due to BCG. This
approach has been used in Venezuela for years, while
attempts are being made to improve the vaccine, since this
is a crude preparation (autoclaved parasites) and BCG
injections (used as a T-cell adjuvant) produce lesions and
leave scars. This preparation however, has not been effica-
cious as a prophylactic vaccine against CL. Similarly,
Mayrink and his colleagues have used killed Leishmania
without any adjuvant in Brazil and Colombia, again
showing no prophylactic efficacy. However, the killed L.
amazonensis vaccine was highly efficacious when used as
an adjunct to low dose chemotherapy. In a double blind,
sequential enrolment of 100 patients (96 evaluable), two-
arm trial, the efficacy of 8 mg/Kg/d Sb+5 (low dose) for 4
cycles (10 daily injection followed by 10 day rest = one
cycle) was compared to that of the low dose Sb+5 plus 4
cycles of killed Leishmania  vaccine. At the end of the
treatment47/47 (100%) of patients in combined
immuno-chemotherapy group were completely cured vs.
4/49 (8%) in the low chemotherapy alone group (Fig 11).
With this impressive data and previous smaller trials, this
preparation was registered in Brazil as a therapeutic vac-
cine, adjunct to low dose Sb+5 treatments [8]. The advan-
tage of this approach is the reduction in cost and side
effects due to full course of antimonials, but the disadvan-
Schematic representation of the mode of action of Imiquimod Figure 9
Schematic representation of the mode of action of Imiquimod. IFN-γ = Interferon-gamma, IL-12 = Interleukin-12, 
MHC-II = Type 2 major histocompatibility antigen, NO = Nitrous oxide, TCR = T-cell receptor, Th1 = T-helper cell type 1, 
Th0 = Undifferentiated T-cells, TLR-7 = Toll like receptor-7. (presented by G. Matlashewski)
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tages are long duration of treatment and the requirement
for daily injections.
Discussion: All these results with the first generation
vaccines (killed parasites) should be taken as proof of
principle. It is well known in leishmaniasis that the
immune response is an intricate part of recovery from
Leishmania infection. It is therefore logical that with the
modulation of the immune mechanism toward the pro-
tective immune response during therapy cure would be
enhanced. The first generation vaccines are very inex-
pensive and safe as they have been given to tens of
thousands of healthy humans in prophylactic trials as
well as patients for therapy. However, they are crude
preparations and not as yet fully standardized. In addi-
tion, the parasites are grown in media containing fetal
Response to Immunochemotherapy of CL in Peru Figure 10
Response to Immunochemotherapy of CL in Peru. Double-blind randomized placebo-controlled trial of topical Imiqui-
mod plus antimony vs placebo plus antimony. Forty subjects with clinical resistance to antimony received Sb+5 (20 mg/kg/day im 
or iv) and were randomized to receive either topical imiquimod 5% cream (Aldara; 3 M Pharmaceuticals) or vehicle control 
every other day for 20 days. With permission from Miranda et al. Clin. Infect. Dis. 2005, 40: 1395.
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calf serum, although it is possible to grow Leishmania in
defined media. The alternative, the only one second
generation vaccine, is in early clinical development
[9,10]and not considering the cost which would most
likely be prohibitive, the efficacy results would not be
available for several years. Therefore, until a better vac-
cine becomes available, two avenues could be consid-
ered
a- To a short course of chemotherapy add immuno-
modulators without leishmanial antigens (i.e. Imiqui-
mod, see Matlashewsky) or,
b- To a short course of chemotherapy add a vaccine
composed of an adjuvant and a standardized first gen-
eration vaccine produced with all current GMP require-
ments. Killed Leishmania plus CpG has been shown to
be a potent vaccine in mice (see Sacks, below).
It was considered that immunotherapy combined with
short course of chemotherapy is an innovative
approach and an opportunity not fully explored for
leishmaniasis, though well advanced in oncology and
other human diseases. DNDi is in a good position to
launch this innovative modality for treatment of leish-
maniasis.
Dr E. Khalil was unable to attend. The recent trial of his
group on immuno-chemotherapy of persistent PKDL
cases in Sudan using alum-autoclaved L. major + BCG
(alum-ALM vaccine) was briefly presented by Dr Modab-
ber. About 50% of treated VL patients develop PKDL and
although 85% of the cases who are generally leishmanin
skin test (LST) positive self heal within 1 year or respond
to 30–40 days of Sb+5 treatment. Treatment of the
remaining 15% in whom the disease persists for many
years, is difficult, prolonged, and expensive and it often
Immuno-chemotherapy of CL caused by L. braziliensis in Brazil Figure 11
Immuno-chemotherapy of CL caused by L. braziliensis in Brazil. Double-blind controlled trial of Mayrink's vaccine 
(killed L. amazonensis) plus low dose (8 mg/Kg/d) Sb+5 vs. low dose Sb+5. Patients received daily injections of the combination or 
drug alone for 10 days followed by 10-day rest (one cycle). All patients (47/47) were cured in the combination group after 4 
cycles (80 days) vs. 4/47 in the chemotherapy alone group. The non-responders were rescued with full dose antimony. 
(Adopted from Machado-Pinto et al. Int. J. Dermat. 2002; 41:73-8.)
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fails. The alum-ALM vaccine has been shown to be safe
and induce primarily a Th1 response and LST conversion
in almost 100% of Sudanese volunteers. Following the
concept used in Venezuela and Brazil, the Alum-ALM vac-
cine was added to the standard Sb+5 treatment for persist-
ent PKDL patients. Following several small safety/
immunogenicity trials of Alum-ALM alone or alum-ALM
vaccine with or without antimonial in 5–8 persistent
PKDL patients, a hospital based, randomized and double
blind study was conducted with thirty patients, to further
study the safety of vaccine and see if addition of the vac-
cine to the standard chemotherapy would enhance cure.
On day 60, a total of 12/15(87%) patients in immuno-
chemotherapy group (4 weekly injection of vaccine +
daily Sb+5) were cured and the remaining showed consid-
erable improvement. On the other hand only 8/15 (53%)
of the patients who received antimonial alone healed
completely within 60 days and the remaining failed to
show any improvement (Fig 12). There were no relapse
cases in the first group but 2 relapse cases in the antimo-
nial group. The leishmanin skin induration increased sig-
nificantly at day 60 in antimony/vaccine arm (p = 0.004)
but not in the antimony-alone arm (p = 0.06). The leish-
mania-specific IFN-γ production in vitro on day 21 was sig-
nificantly higher in the immuno-chmotherapy Vaccine
arm compared to the chemotherapy alone arm (p  =
0.002). The levels dropped to baseline by day 60.
Discussion: The results are highly encouraging, but this
is a preliminary hospital based study and a larger trial
is needed to see the exact efficacy and applicability of
this approach in the field. PKDL cases are most likely
the reservoir of infection and their treatment must be
considered an important target for the control of VL in
Sudan.
Dr D. Sacks introduced Oligodeoxynucleotides (ODN)
containing CpG motifs which have been used as adju-
vants in experimental animals for prevention and treat-
ment of CL[9]. The CpG's are rapidly internalized by
immune cells (B cells, macrophages, dendritic cells and
monocytes) and localize to endocytic vesicles where they
interact with Toll-like receptor 9 (TLR9). TLR9-bearing
cells recognize and respond to non-methylated CpG
motifs (present at high frequency in bacterial but not ver-
tebrate DNA), triggering an immune cascade character-
ized by polyclonal-B-cell activation, improved antigen
uptake/presentation by antigen-presenting cells, and the
secretion of chemokines and pro-inflammatory cytokines,
including IL-12, IL-18, TNF-α, IFN-α, -β and -γ, that foster
a strong Th1 response. In this regard, CpG ODN show
promise as immuno-protective agents and as vaccine
adjuvants. Extensive work in murine models of CL has
shown that CpG ODNs can be used as an effective adju-
vant with killed parasite and sub-unit vaccines against L.
major, and as immunotherapy to reduce the severity and
promote the clearance of L. major (Fig 13). Application of
CpG soon before or after a live inoculum, can significantly
reduce the pathology of the inoculum without reducing
its protective potential against new challenge. It may
therefore be considered as an adjunct to live parasite vac-
cine.
In addition, CpG administration has been shown to pro-
mote healing of an active lesion in experimental CL.
Discussion: Development of CpG's as adjunct to chem-
otherapy of CL either alone or in combination with
leishmanial antigens should be considered. The long
lasting effect of CpG's when used with killed parasite
vaccine in animal models makes them a good candidate
in line with the view of reducing the need for patient –
health worker contact discussed and included in the
recommended TPP for CL.
Dr. Asrat Hailu presented clinical characteristics of local-
ized, mucocutaneous and diffuse cutaneous leishmaniasis
in Ethiopia. About 85% of CL in Ethiopia is caused by L.
aethiopica. The rest is caused by L. tropica and L. major. CL
caused by L. aethiopica is generally self healing, however
the sequels include diffuse and mucosal leishmaniasis in
and a small % of cases. Lesions caused by L. aethiopica do
not respond to Sb+5. The in vitro ED50 values for Sb+5, ami-
nosidine sulphate and pentamidine were 25.3 μg Sbv/ml,
6.4 μM and 0.6 μM respectively. This in vitro study, dem-
onstrated the poor activity of antimoniate on L. aethiopica
lesions. Cryotherapy was apparently associated with heal-
ing but with a high incidence of intensely hypochromic
scars. An efficacious, safe and affordable treatment is
needed for CL in Ethiopia which is a public health prob-
lem due to stigma associated with severe and disfiguring
lesions, long duration of illness, and severe sequels.
Discussion: L. aethiopica is a unique organism unlike
other species. Although it is a neglected disease, a spe-
cial strategy may not be justified at this time. However,
the new strategies for ACL should be tested against L.
aethiopica lesion.
Conclusion and recommendations
The major conclusions and recommendations can be
summarized as follows:
The global burden of cutaneous leishmaniasis was dis-
cussed with respect to
￿ Financial impact on the lives of CL cases, who in general
are amongst the most under privileged population in
endemic countries – the close association between pov-
erty and CL incidence in many countries was notedKinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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￿ The stigma associated with the lesion and scar of CL,
particularly in young women leading to suffering and
marginalization
￿ The financial burden and its impact on health systems
of disease endemic countries
￿ Absence of a vaccine and lack of satisfactory (safe,
affordable and efficacious) drugs
￿ The diversity of epidemiological characteristics of foci of
CL in Africa, Asia, Europe and Latin America due to varie-
ties in causative Leishmania  species, their vectors and
mammalian reservoir hosts
￿ Difficulties in control of CL due to lack of effective,
affordable, easily implemented tools
￿ Lack of political will and resources to maintain control
activities
￿ Lack of involvement of the pharmaceutical/biotechnol-
ogy sector in the development of new drugs and vaccines
It was generally agreed that our knowledge of the inci-
dence, prevalence and socio-economic impact of CL was
limited. Prevalence is high, stigma associated with the dis-
ease is well known and the burden on individuals and
governments are well recognized, but we have limited
quantitative data. The disease is not generally reported
and there is a paucity of socio-economic studies as well as
high quality clinical trials in accordance with interna-
tional standards of Good Clinical Practices (GCP). The
first line drugs (antimonials, developed over 60 years ago)
have serious side effects, require repeated injections, are
expensive, not always available and in many parts of the
endemic regions have become ineffective. Therefore,
patients in endemic areas resort to whatever local treat-
ments available, including burning, application of acids,
herbal concoctions, curettage, etc. Victims are mostly chil-
dren in endemic foci and lesions are frequently on the
face.
Since CL comprises different disease forms that cannot
necessarily be addressed by one and the same treatment,
it was decided to set criteria through which CL with differ-
ent (epidemiological) characteristics could be prioritized
as targets for the development of a new treatment. These
criteria included:
￿ Severity of the disease, including duration of disease,
average size of lesions and number of lesions per patient
and severity of scars
￿ Lack of response to available drugs
￿ The overall incidence and prevalence of the disease
(based on available data)
￿ Sequelae of the disease, including leishmaniasis recidi-
vans (a long-lasting relapsing form of CL often located on
the face) and mucosal disease
￿ Public health aspects, including the impact of treatment
of individuals on control of transmission of Leishmania
spp, the etiological agent (s) of leishmaniasis
￿ Lack of major efforts in drug development
While it was unanimously agreed that new and improved
treatments are needed for all forms of CL, some forms
may represent a higher priority or opportunity for targeted
R&D efforts.
Based on the above considerations, the anthroponotic CL
(ACL) and its sequelae, Leishmaniasis Recidivans (LR)
caused by L. tropica in the Old World was proposed as the
priority target. In ACL, the cutaneous lesion may self heal
in a year or longer but leaves an unsightly scar for the life
Immuno-chemotherapy of persistent PKDL patients in Sudan Figure 12
Immuno-chemotherapy of persistent PKDL patients 
in Sudan. Double-blind randomized antimony alone control-
led vs. immunochemotherapy trial of 30 persistent PKDL 
patients. All patients received the standard daily injections of 
Sodium Stibo-Gluconate (SSB) for 40 days. Patients were 
randomized to receive 4 weekly injections of alum-precipi-
tated autoclaved L. major (alum-ALM) + one tenth of normal 
dose of BCG or a placebo (BCG diluent). On day 60, 87% in 
the combined immuno-chemotherapy group were cured and 
the rest improved vs. 53% in chemotherapy alone group 
cured and the rest failed (efficacy = 72%, 95% CI: 0.8–1.18). 
By day 90 all patients in immunochemotherapy had cured vs. 
Adopted from Musa, A. & Khalil, EAG, et al.)
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of the patients. In 2–5% of cases, ACL becomes chronic or
can develop into LR, a persistent presence of parasites that
are able to expand and drive a cutaneous lesion around
the original lesions during the course of the primary
lesions or long after healing. Recent data indicate that ACL
does not respond well to antimonials nor to some of the
second generation drugs tested. It is highly prevalent in
South-, South Western countries of Asia where it repre-
sents a major public health problem. The most affected
populations live in Afghanistan, Pakistan, Iran, Iraq, Tur-
key and Syria. ACL is an anthroponotic CL, transmitted
from human to human by the bites of sandfly vectors.
Although in rare cases foxes and stray dogs have been
shown to be infected by L. tropica, they are not considered
as primary reservoir. Hence, based on epidemiological
characteristics (sandfly specificity, urban-, chronic and the
anthroponotic nature of ACL), treatment of cases is
believed to reduce the size of parasite reservoir and
thereby reduce transmission. The dynamics of the trans-
mission need to be further elucidated.
As a second priority target, CL (and ML) caused by L. bra-
ziliensis in the New World was put forward. This CL occurs
in most endemic countries of Latin America and is consid-
ered a major public health problem in Brazil, Bolivia,
Peru, Venezuela and Guatemala. A dreaded sequel of this
CL is mucosal/mucocutaneaous leishmaniasis (ML) that,
unless diagnosed and treated early, will cause destruction
Immunotherapy of CL lesions in macaque monkeys Figure 13
Immunotherapy of CL lesions in macaque monkeys. Systemic administration of oligo-deoxy-nucleotide (ODN) class D/
A limits the size of lesions following an intradermal infection with L. major. Importantly, the reduced morbidity was not associ-
ated with a reduction in long-term immunity, as such treated macaques were still protected following a secondary challenge. 
This suggests a potential role for CpG ODN in L. major treatment. These findings support the development of clinical studies 
to assess the use of CpG ODN types D/A as immunoprotective and therapeutic agents. (From Flyn B. et al Infect.& Immun. 
73:4948, 2005 with permission)
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of nasal septum, oral cavity, pharynges and larynges dis-
figuration and in some cases death. Many suicides or
attempts have been recorded due to the stigma associated
with ML. Prolonged and high dose treatment with anti-
monials is required for cure which is both beyond the
means of most patients and associated with side effects
due to the drugs. The best way to prevent ML is prevention
or timely and adequate treatment of CL in the L. brazilien-
sis endemic region.
To guide the R&D efforts, a Target Product Profile (TPP)
was established for ACL (See Appendix 1. ACL-TPP.xls)
with a strong emphasis on safety, efficacy, cost, quality of
scar and reduced interaction with "health system". The
new treatment should aim for a short treatment period
and minimize the need for patient-health-worker contact.
Although a new treatment for ACL might not be effective
against CL caused by other spp of Leishmania, some CL's
may still respond to it. Similarly, a treatment being devel-
oped for CL caused by L. major may turn out also to be
effective against ACL (e.g. topical aminoglycosides). So it
will be critical to systematically assess possible new treat-
ments for one form of CL in other manifestations of the
disease.
Other than paromomycin and limited studies with milte-
fosine, there are no highly efficacious drugs or candidates
in advanced stages of development, nor a screening pro-
gram in place for the identification and evaluation of new
chemical entities active against the pathogens that cause
target CL. Moreover, there are no validated animal models
for compound evaluation against L. tropica. The recently
developed luciferase expressing L. major – C57Bl/6 mouse
model allowing real-time measurement of parasite load
simultaneously with monitoring lesion development and
healing, provides a convenient way to assess new com-
pounds and drug candidates, and would be very useful if
adapted to various target spp of both Old World and New
World Leishmania.
One promising approach with long term potential is to
combine chemotherapy with immuno-modulating
agents. The underlying mechanism of the body for con-
trolling  Leishmania  multiplication and spread, and to
achieve a stable self-healing process of lesions is an ade-
quate immune response. It is the development of effector
cells capable of eliminating parasites (predominantly ini-
tiated by CD4 and CD8 T lymphocytes that are tightly reg-
ulated by counter-inflammatory immune effector cells)
that leads to cure and maintains the persisting parasites
under control. Treatment of immuno-compromised
patients is invariably associated with relapse. Therefore,
an initial elimination of the Leishmania parasites by chem-
otherapy and the induction of a adequately balanced cel-
lular immune response could lead to quick recovery and
control of persisting non-dividing parasites. Immuno-
therapy can take the form of immunomodulators alone or
in combination with Leishmania antigens.
There is currently no adequately effective vaccine; how-
ever, killed parasites when given together with some adju-
vants (First Generation Vaccine, FGV). Although effective
as prophylactic vaccine in experimental models, FGV do
not protect against human CL. Nevertheless, FGV's have
shown positive results as" therapeutic" vaccines for CL
(Brazil & Venezuela), and for persistent PKDL patients in
Sudan). These results are encouraging proofs of principle,
but such crude preparations of killed parasite are not
acceptable as final vaccines. More recently, defined anti-
gens of Leishmania used together with Granulocyte-Mac-
rophage Colony Stimulating Factor as adjuvant have been
shown to cure drug refractory ML patients in a preliminary
trial [10] One second generation vaccine (SGV, 3 recom-
binant Leishmania antigens + a new adjuvant) is in clinical
development (phase I) as a therapeutic vaccine [11]. The
early results of a safety and immunogenicity trial in Peru
indicate that addition of Leish-111f +MPL-SE to chemo-
therapy ofML patients is safe and there is anindication
thatthe time to cure may be reduced, compared to chem-
otherapy alone. Further studies are needed.
On the level of immuno-chemotherapy, in addition to
cytokines, several chemical immunomodulators have
been tested in combination with standard chemotherapy
in humans (imiquimod) or various CpG's in mice and
monkey models of CL. Currently, a clinical trial with imi-
quimod as adjunct therapy to antimonials is being carried
out in Peru with support from DNDi. There are several
CpG's in clinical trials for other diseases, i.e. cancer (CpG
7909 and Vaximmune of Coley; dSLIM of Mologen, etc.).
Actilon is now marketed for hepatitis C treatment. The
CpG's are species specific (except dSLIM, which is not and
works in mice and humans) and different motifs act as
agonists of various Toll Like Receptors (TLR). Due to our
knowledge of immunology of leishmaniasis (at least in
mice), the specific CpG-ODN's for targeted TLR can be
selected to induce the desired immune response. The
development of these agents should be followed closely
and those appropriate for leishmaniasis should be pur-
sued for for development against CL.
Specific recommendations
CL in all its forms can be considered as a neglected dis-
ease, and organizations such as DNDi, WHO and TDR
should place it on their list of target diseases for specific
R&D efforts to develop improved control measures.Kinetoplastid Biology and Disease 2007, 6:3 http://www.kinetoplastids.com/content/6/1/3
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Efforts should initially focus on Anthroponotic CL due to
L. tropica (ACL) and CL caused by L. braziliensis.
Target short term objectives
￿ Part of the reason for CL's neglect is related to the lack of
reliable and meaningful data on the impact of the disease.
Quality multi-center impact studies are needed to better
assess the socio-economic burden and human suffering
caused by the different forms of CL, with priority on ACL
due to L. tropica and CL caused by L. braziliensis.
￿ The quality of clinical trials should be enhanced. It is
essential to establish protocol templates in line with cur-
rent Good Clinical Practices (c-GCP) and provide training
and coordination. In addition, to increase the compara-
bility of clinical trial outcomes, a standardized clinical
trial methodology for CL should be developed, including
guidelines on inclusion/exclusion criteria, clinical end-
points, test of cure, etc.
￿ Short course of chemotherapy together with immune
modulators alone or immune-modulators plus Leishma-
nia antigens (therapeutic vaccines) should be given seri-
ous consideration.
 The possible value of further investing FGV should be
assessed, while the further development of SGV should be
closely monitored, and supported if needed.
 The new CpG oligodeoxynucleotide adjuvants have
encouraging results in experimental leishmaniasis. As
soon as the safety profile is established in clinical oncol-
ogy or other diseases, CpGs (with or without leishmanial
antigens but with anti-leishmanial drugs) should be
tested in clinical trials in CL.
 The field of immuno-modulators is a vibrant field of
research, driven by their promise for the treatment of
other diseases such as cancer. These developments should
be closely monitored as new immunomodulators reach-
ing the market could also show promise in CL.
￿ Clinical trials with drug combination should be initi-
ated with the view of shortening treatment period and
reducing cost and need for follow up.
￿ Based on the outcome of the clinical trials of the new
topical amino-glycoside formulations, their efficacy
against other forms of CL, in particular ACL should be
determined.
Target long term objectives
￿ New chemical entities and drugs emerging from ongo-
ing efforts to develop drugs for visceral leishmaniasis (VL)
should be screened for activity against L. tropica and L. bra-
ziliensis. In case of good activity, the possibility and
requirements for a parallel development for VL and CL
should be explored.
￿ The new luciferase expressing L. major – C57Bl/6 mouse
model should be fully exploited for assessing in vivo anti-
leishmanial activities of drugs/compounds; even though
it is not at present adapted to L. tropica/L. braziliensis.
Attempts could be made to adapt this model for L. tropica.
Other possible models (i.e. hamster and L. braziliensis) to
be considered for development, but relevance to be
decided on a case by case basis.
￿ The development of new vaccines and adjuvants/
immuno-modulators with promise for CL should be
closely monitored, with the view of potential use for
immunotherapy of ACL (and later CL due to L. brazilien-
sis). This would require further clinical trials.
￿ Topical treatment of CL is preferable to systemic inter-
ventions. Further research and studies to improve delivery
and efficacy of topical treatment based upon new technol-
ogies needs to be supported.
Based on these objectives, two decision matrices were
developed for short- and long-term objectives respectively
(Figs. 1 &2).
Conclusion
Cutaneous leishmaniasis is highly neglected, requiring
new and improved treatment options that are effective
against the different forms of the disease. A realistic assess-
ment of the impact of control and treatment on public
health and needs of patients is required. An improved and
more standardized design of clinical trials should be
developed, and efforts are needed to improve the quality
of the clinical trials according to current GCP. New drugs
and immuno-therapeutics are required to improve current
treatment options; drug combinations involving either or
both chemotherapeutics and immunomodulators have
the potential to increase efficacy, reduce treatment dura-
tion and improve ease of use and compliance. There is a
need for a coordinated response to address these issues.
Abreviations
ACL, Anthroponotic cutaneous leishmaniasis
ALM Autoclaved Leishmania major
ANVISA The Brazilian regulatory agency
BCG Bacillus Calmette-Guérin
BPQ Buparvaquone, 3-POM-BPQ = 3phosphono-oxyme-
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CL Cutaneous leishmaniasis
CpG, Cytosine phosphate guanosine oligodeoxynucle-
otide
DALY Disability adjusted life year
DBRPC Double blind, randomized, placebo-controlled
DNDi Drugs for neglected diseases initiative
FDA The United States food and drug administration
FGV First generation vaccine (whole parasite)
GCP-ICH Good clinical practices-International confer-
ence on harmonization
GMP Good manufacturing practices
IFN Interferon
IL-12 Interleukin-12
IP Institut Pasteur, Paris
LR Leishmaniasis recidivans
LST Leishmanin skin test
ML Mucosal- or mucocutaneous leishmaniasis
μM Micro-mole
ODN Oligodeoxynuceotide
PCR Polymerace chain reaction
PKDL Post kala azar dermal leishmaniasis
QT interval of time from the start of the Q wave to the end
of the T wave in the heart's electrical cycle.
R&D Research and development
Sb+5 Pentavalent antimony
SGV Second generation vaccine (defined vaccine)
T h Thymus derived helper cell
TDR The Unicef-UNDP-WHO-World Bank special pro-
gram on research and training in tropical diseases
TLR Toll like receptor
TNF Tumor necrosis factor
TPP Target product profile
USAMRMC, US Army Medical Research and Materiel
Command
WHO World Health Organization
WRAIR Walter Reed Army Institute of Research
ZCL Zoonotic cutaneous leishmaniasis (here referred to
CL caused by L. major)
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